ECO Animal Health Group plc
("ECO" or the "Company")
ECO Animal Health General meeting resolution passed
ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announces that at its General Meeting held earlier today ("GM") the special resolution proposed to the meeting to allow the Company to make market purchases of its own shares was duly passed.
Proxy votes received in relation to the resolution were as follows:
| Resolution | For |
% |
Discretionary |
% | Against |
% | Withheld |
| 01 | 40,553,465 | 97.6 | Nil | 0 | 1,011,642 | 2.4 | Nil |
As previously announced the Company disposed of certain surplus freehold properties and received net proceeds of £1,058,454. The board stated that it intends to use the majority of these proceeds to advance the growth aspirations of ECO. The Board also announced that it intends to use some of the proceeds to purchase ordinary shares of the Company ("Ordinary Shares") in the market to cover possible future vesting of employee share-based incentives. The authority conferred by this resolution will be used to purchase a maximum of 270,000 Ordinary Shares in the market which is expected to cost no more than £300,000.
In addition, in the remaining weeks before the close of the financial year ending 31 March 2024, the Company intends to issue a trading update.
David Hallas, CEO of ECO, commented: "We are pleased to have received approval from our shareholders enabling us to pursue this one-off share purchase. The Board agreed that now is the optimal time to use proceeds from our recent property disposals to purchase shares that will be used to satisfy share based staff incentives."
-Ends-
For further information please contact:
| |
About ECO Animal Health
ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.
Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.
Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry.
Click here for more information: https://ecoanimalhealth.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.